الفهرس 
TitleOnly 14 pages are availabe for public view
 |  | from | 94 |  |  |
| | | from | 94 | | |
Abstract
Breast cancer is the most common neoplasm among women in the majority of the
developed countries, accounting for one-third of newly diagnosed malignancies.
Breast cancer is a complex disease encompassing multiple tumor entities, each
characterized by distinct morphology, behavior and clinical implications. Besides estrogen
receptor, progesterone receptor and human epidermal growth factor receptor 2, novel
biomarkers have shown their prognostic and predictive values.
MicroRNAs are short 18-22 nucleotide non-coding RNAs that may alter gene
expression by binding messenger RNAs (mRNAs), and may affect cell proliferation,
differentiation, and cell death. Cancer associated microRNAs may be oncogenic, or tumor
suppressive, with oncogenic microRNAs promoting tumor growth, and tumor suppressive
microRNAs being suppressed in cancer. They may be a potential biomarker, as they are
released by all cell types via exosomes and may be detected at any tumor stage.
MicroRNA21 is an onco-microRNA. There is a large amount of evidence indicating
that microRNA21 is associated with regulation of cellular proliferation and differentiation
during development. Also, it is possible to develop treatment strategies by targeting
microRNA 21.
The present study was designed to identify serum microRNA21 expression in breast
cancer Egyptian females. To achieve this goal this study was conducted on 52 BC female
patients and 28 controls.
All patients had:
1- Clinical and physical evaluation to exclude any other diseases.
2- Full pathological identification of hormonal receptors (ER,PR HER2) ,tumor
stage , grade and lymph node metastasis.
3- CA15.3serum level.
4- Total RNA was extracted from serum samples followed by reverse transcription
real time PCR. Serum microRNA21 was measured using qPCR. Expression of
serum microRNA21was calculated using the comparative cycle threshold (CT)
method (2–ΔΔCT).
Statistical analysis of the studied parameters showed the following results:
Micro RNA21 serum expression level was significantly higher in BC patients than
in control group although 94.2% of the patients group were in early stage I and II.
This may emphasize its value as biomarker for breast cancer in its early stages.
Accuracy has been determined by plotting a receiver-operating characteristic
(ROC) curve. AUC was 0.94 At the cut-off value of 0.82, the sensitivity and specificity of serum microRNA 21
expression levels was 100%, 35.7% respectively. Positive predictive value was
74.2% and negative predictive value was 100%.
Micro RNA21 serum expression level showed significant correlation with serum
CA15.3.
Our study had some limitations, including small sample size and a limited ability to
generalize our results since all our patients were Egyptian females